

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/015,332	12/12/2001	Anne-Laure Grillot	VPI/00-128US	2964
75	90 04/07/2003			
Tina M. Powers			EXAMINER	
VERTEX PHARMACEUTICALS INC. 130 Waverly Street			RAO, DEEPAK R	
Cambridge, MA	02139-4242		ART UNIT	PAPER NUMBER
			1624	3
			DATE MAILED: 04/07/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 10/015,332

tion No. Applicant(s)

Grillot et al.

Examiner

Office Action Summary

Deepak Rao

1624

Art Unit



Davis of 4	The MAILING DATE of this communication appears of	on the cover sheet with the correspondence address
	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE 1 MONTH(S) EROM
	MAILING DATE OF THIS COMMUNICATION.	TO EXTINE INIONTR(3) FROM
	· · · · · · · · · · · · · · · · · · ·	no event, however, may a repty be timely filed after SIX (6) MONTHS from the
- If the p	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	
	period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause th	
	ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nis communication, even if timely filed, may reduce any
Status		
1) 💢	Responsive to communication(s) filed on <u>Dec 12, 2</u>	001 .
2a) 🗌	This action is FINAL . 2b) ☑ This action	on is non-final.
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex par	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 💢	Claim(s) 1-56	
4	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 🗆	Claim(s)	is/are rejected.
7) 🗆	Claim(s)	is/are objected to.
8) 💢	Claims <u>1-56</u>	are subject to restriction and/or election requirement.
	tion Papers	
9) 🗌	The specification is objected to by the Examiner.	
10)□	The drawing(s) filed on is/are	a) accepted or b) objected to by the Examiner.
	Applicant may not request that any objection to the de	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11)		is: a) \square approved b) \square disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	
12)	The oath or declaration is objected to by the Examin	ner.
	under 35 U.S.C. §§ 119 and 120	
13)□	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).
a) [☐ All b)☐ Some* c)☐ None of:	
	1. Certified copies of the priority documents have	e been received.
,	c	e been received in Application No
:		ocuments have been received in this National Stage
*S	ee the attached detailed Office action for a list of the	
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a) □	The translation of the foreign language provisiona	application has been received.
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachm	ent(s)	
	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) ∐ Inf	ormstion Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:

Application/Control Number: 10/015,332 Page 2

Art Unit: 1624

DETAILED ACTION

Claims 1-56 are pending in this application.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 41-56, drawn to compounds formula IIa or IIb and corresponding composition, classified in class 544-548/ various subclasses.
- II. Claims 1-18, drawn to a method of decreasing bacterial quantity in a biological sample, classified in class 435, various subclasses.
- III. Claims 19-40, drawn to a method of treating a bacterial infection in a mammal, classified in class 514, various subclasses.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product is useful in materially different processes of using. Also, the processes of each of inventions II and III can be practiced with materially different products.

Application/Control Number: 10/015,332 Page 3

Art Unit: 1624

Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions and/or effects.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Claims 1-56 are generic to a plurality of disclosed patentably distinct species comprising the species disclosed in the specification. In addition to the election of a single invention from above, applicant is required under 35 U.S.C. 121 to elect a single disclosed species falling within the elected group, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/015,332

Art Unit: 1624

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Deepak Rao whose telephone number is (703) 305-1879. The examiner

can normally be reached on Tuesday-Friday from 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Dr. Mukund Shah, can be reached on (703) 308-4716. The fax phone number for the

organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-1235.

Deepak Rao

Page 4

Primary Examiner

Art Unit 1624

April 6, 2003